drugset / Trial / NCT07219368
A First-in-Human Single and Multiple Ascending Dose Study of MT-201
RandomizedSingle-groupDouble-blindOther
Summary
First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-201 in healthy participants.
Timeline
- Start
- 2025-10-08
- Primary completion
- 2026-11-24
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adecatumumab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.